抗CD20单克隆抗体对比传统合成改善病情抗风湿药在抗Jo-1抗体阳性抗合成酶综合征中的有效性与安全性:回顾性队列研究
在仁济医院2007—2023年128例抗Jo-1抗体阳性抗合成酶综合征患者中提取166个治疗方案,经倾向性评分匹配49对CD20单抗与csDMARD使用者;CD20单抗组达到低疾病活动度的比例显著高于csDMARD组(46.9% vs 22.4%,p=0.011),主要感染暴露调整发生率两组无显著差异(RR=1.22,95%CI 0.64—2.36)。
要点
- CD20单抗组低疾病活动度达成率46.9%,高于csDMARD组的22.4%(p=0.011)。
- 主要感染暴露调整发生率CD20单抗组7.911/100患者年 vs csDMARD组6.479/100患者年,无显著差异(RR=1.22,95%CI 0.64—2.36)。
- 敏感性分析进一步证实CD20单抗有效性优于csDMARD。
核心结论
- CD20单抗在抗Jo-1抗体阳性抗合成酶综合征患者中表现出显著疗效和可接受的安全性。
- 包括本研究在内的累积证据提示,CD20单抗应被考虑作为抗Jo-1抗体阳性抗合成酶综合征的一线选择。
研究设计与样本
- 单中心回顾性队列研究,收集中国仁济医院2007—2023年抗Jo-1抗体阳性抗合成酶综合征患者。
- 采用流行新用户设计,以时间为基础的倾向性评分、不放回匹配CD20单抗与csDMARD使用者。
- 从128例患者中提取166个符合条件的治疗方案,中位随访5年,最终匹配49对CD20单抗与csDMARD处方。
主要发现
- CD20单抗组达到低疾病活动度(5项LDA)的比例为46.9%,csDMARD组为22.4%,差异有统计学意义(p=0.011)。
- 主要感染的暴露调整发生率CD20单抗组为7.911/100患者年,csDMARD组为6.479/100患者年,两组无显著差异(RR=1.22;95%CI 0.64—2.36)。
- 敏感性分析进一步证实CD20单抗相较于csDMARD的疗效优势具有稳健性。
关键数值与推荐
- 低疾病活动度(5项LDA)定义为无活动性关节炎、肌炎、间质性肺病、发热,且泼尼松剂量≤7.5 mg/天。
临床怎么用
- 作者认为,包括本研究在内的累积证据提示CD20单抗应被考虑作为抗Jo-1抗体阳性抗合成酶综合征的一线选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Anti-Jo-1 antisynthetase syndrome (Jo1+ASyS) is the most common form of idiopathic inflammatory myopathy with high relapse rates and limited treatment options beyond csDMARDs, which frequently fail to achieve adequate disease control. This study aimed to evaluate the efficacy and safety of anti-CD20 monoclonal antibodies (CD20mAbs) compared to conventional synthetic(cs) DMARDs in patients with Jo1+ASyS. METHODS: A single-center retrospective cohort of patients with Jo1+ASyS were collected at RenJi Hospital in China (2007-2023). A prevalent new-user design with time-based propensity scores, applied without replacement, was used to match CD20mAb and csDMARD users. The primary outcome was the percentage of patients reaching Low Disease Activity (5-item LDA), as defined by the absence of active arthritis, myositis, ILD, fever, and prednisone dosage ≤7.5 mg/day. RESULTS: A total of 166 eligible treatment regimens, including CD20mAbs and csDMARDs, were extracted from 128 Jo1+ASyS patients with a median follow-up period of 5 years. Utilizing propensity score, 49 pairs of individual prescriptions for CD20mAbs and csDMARDs users were matched. The group treated with CD20mAbs exhibited a significantly higher rate of achieving LDA compared to those treated with csDMARDs (46.9 % vs. 22.4 %, p = 0.011). No significant differences in exposure-adjusted incidence rate were detected between the two treatment modalities (CD20mAbs vs. csDMARDs = 7.911 vs. 6.479 per 100 patient-yr, RR = 1.22; 95 % CI: 0.64, 2.36), with respect to major infections. Sensitivity analyses further confirmed the robustness of the superior effectiveness of the CD20mAbs compared to the csDMARDs. CONCLUSION: CD20mAbs exhibited remarkable treatment efficacy and acceptable safety in patients with Jo1+ASyS. Cumulative evidence, including ours suggested that CD20mAbs should be considered as a first-line option for Jo1+ASyS.
引用
- Sun S, Jin J, Chen J, et al. Effectiveness and safety of anti-CD20 monoclonal antibodies versus csDMARDs in anti-Jo-1 antisynthetase syndrome: A retrospective cohort study. Semin Arthritis Rheum. 2025. PMID: 40122014. doi:10.1016/j.semarthrit.2025.152712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。